NOVAVAX to Report Third Quarter 2011 Financial Results on November 4, 2011
ROCKVILLE, Md., Oct 28, 2011 (GlobeNewswire via COMTEX) --
Novavax, Inc. (Nasdaq:NVAX) will report financial results for the third fiscal quarter of 2011 on Friday, November 4, 2011, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call hosted by Stanley C. Erck, President and Chief Executive Officer, and other members of senior management at 10:00 a.m. Eastern time. The webcast and conference call will be available at www.novavax.com under Investors/Events. The dial-in number for the conference call is 1-877-212-6076 (domestic) or 1-707-287-9331 (international). Webcast and telephone replays of the conference call will be available shortly after the completion of the call. To access the replay, dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and use passcode 23074432.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website: www.novavax.com.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Novavax, Inc.
CONTACT: Frederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000